A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (NCT06012435)
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE SIGVOTATUG VEDOTIN COMPARED WITH DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (BE6A LUNG-01)
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an anti-PD-(L)1 drug. Participants with tumors that have certain treatable genomic alterations must have had at least 1 drug for that genomic alteration, in addition to platinum-based chemotherapy. This clinical trial uses an experimental drug called sigvotatug vedotin, which is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial also uses a drug called docetaxel. Docetaxel is an anticancer drug that has been approved to treat non-small cell lung cancer. It is usually given to patients who previously received another anticancer treatment. In this study, one group of participants will get sigvotatug vedotin on Days 1 and 15 during each 28-day-cycle. A second group of participants will get docetaxel on Day 1 during each 21-day cycle. This study is being done to see if sigvotatug vedotin works better than docetaxel to treat participants with NSCLC. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Who can join: Review the eligibility criteria below.
Location: Alaska Oncology and Hematology, LLC — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (331 Sites)
Showing the first 25 of 331 sites.
- Alaska Oncology and Hematology, LLC — Anchorage, Alaska
- Providence Medical Foundation — Fullerton, California
- Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center — Fullerton, California
- Providence St. Jude Medical Center — Fullerton, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- Cancer Blood and Specialty Clinic — Los Alamitos, California
- Regulatory Management Only: TRIO-US Central Administration — Los Angeles, California
- Drug Management Only: UCLA West Medical Pharmacy Attn: Steven L. Wong, Pharma.D. — Los Angeles, California
- Drug Management Only: UCLA West Medical Pharmacy, Attn: Steven L Wong, Pharm.D. — Los Angeles, California
- UCSF Medical Center - Mission Bay — San Francisco, California
- Sansum Clinic — Santa Barbara, California
- Sansum Clinic — Solvang, California
- Rocky Mountain Cancer Centers LLP — Aurora, Colorado
- Rocky Mountain Cancer Centers LLP — Boulder, Colorado
- Rocky Mountain Cancer Centers LLP — Colorado Springs, Colorado
- Rocky Mountain Cancer Centers LLP — Colorado Springs, Colorado
- Rocky Mountain Cancer Centers LLP — Denver, Colorado
- Rocky Mountain Cancer Centers LLP — Denver, Colorado
- Rocky Mountain Cancer Centers LLP — Lakewood, Colorado
- Rocky Mountain Cancer Centers LLP — Littleton, Colorado
- Rocky Mountain Cancer Centers LLP — Lone Tree, Colorado
- Rocky Mountain Cancer Centers LLP — Longmont, Colorado
- Rocky Mountain Cancer Centers LLP — Pueblo, Colorado
- Rocky Mountain Cancer Centers LLP — Thornton, Colorado
- Cancer Specialists of North Florida — Fleming Island, Florida
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Non-Small-Cell Lung
- MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
- THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California
Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.